Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Fineline Cube Jan 15, 2026
Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Fineline Cube Jan 15, 2026
Company Deals

Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility

Fineline Cube Jul 31, 2024

Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in...

Company

Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization

Fineline Cube Jul 31, 2024

Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its...

Company Drug

Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA

Fineline Cube Jul 31, 2024

Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...

Policy / Regulatory

China’s NMPA Issues Guidelines for Onsite Inspections of Medical Device Companies

Fineline Cube Jul 31, 2024

The National Medical Products Administration (NMPA) of China has released the “Guidelines for Onsite Inspection...

Company

WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges

Fineline Cube Jul 30, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...

Company Deals

Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business

Fineline Cube Jul 30, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...

Company

Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand

Fineline Cube Jul 30, 2024

Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...

Company Deals

GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines

Fineline Cube Jul 30, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...

Company Drug

Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment

Fineline Cube Jul 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-A1921 Clinical Study in Advanced Solid Tumors

Fineline Cube Jul 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies

Fineline Cube Jul 30, 2024

Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Medical Device

ShuWen Biotech’s Preeclampsia Self-Test Receives NMPA Approval, Marking a Global First

Fineline Cube Jul 30, 2024

Zhejiang-based ShuWen Biotech Co., Ltd has announced that it has received marketing approval from China’s...

Company Deals

Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia

Fineline Cube Jul 30, 2024

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture...

Company Drug

Organon’s Liptruzet Launches in China for Hypercholesterolemia Treatment

Fineline Cube Jul 30, 2024

US pharmaceutical company Organon (NYSE: OGN) has announced the official market launch of its single-tablet...

Company Deals

LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline

Fineline Cube Jul 30, 2024

LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US...

Company Medical Device

Shanghai Sanyou Medical Gains NMPA Approval for 3D Printed Cervical Fusion Device

Fineline Cube Jul 30, 2024

Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a prominent player in the medical device industry...

Company Deals

Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion

Fineline Cube Jul 30, 2024

Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector,...

Policy / Regulatory

China’s H1 2024 Pharmaceutical Trade Data Indicates Mixed Performance in Global Markets

Fineline Cube Jul 30, 2024

The Ministry of Industry and Information Technology (MIIT) has released a report on the first...

Policy / Regulatory

China’s NHC Reports 2023 County Hospital Medical Service Capability Evaluation Results

Fineline Cube Jul 30, 2024

The National Health Commission (NHC) of China has released a notice detailing the results of...

Company Drug

EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi

Fineline Cube Jul 29, 2024

Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...

Posts pagination

1 … 266 267 268 … 610

Recent updates

  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
  • Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
  • Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
  • Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.